Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 14:10:617.
doi: 10.3389/fneur.2019.00617. eCollection 2019.

Mood Effects After Deep Brain Stimulation for Parkinson's Disease: An Update

Affiliations
Review

Mood Effects After Deep Brain Stimulation for Parkinson's Disease: An Update

Ettore A Accolla et al. Front Neurol. .

Abstract

Depression in Parkinson's Disease (PD) is a prevalent and invalidating symptom. Deep brain stimulation (DBS) allows for an improvement of PD motor features, but its effects on mood are difficult to predict. Here, we review the evidence regarding mood effects after DBS of either subthalamic nucleus (STN) or globus pallidus pars interna (GPi). Different influences of multiple factors contribute to impact the neuropsychiatric outcome after surgery. Psychosocial presurgical situation, postsurgical coping mechanisms, dopaminergic treatment modifications, and direct effects of the stimulation of either target are all playing a distinct role on the psychological well-being of patients undergoing DBS. No clear advantage of either target (STN vs. GPi) has been consistently found, both being effective and with a favorable profile on depression symptoms. However, specific patients' characteristics or anatomical considerations can guide the neurosurgeon in the target choice. Further research together with technological advances are expected to confine the stimulation area within dysfunctional circuits causing motor symptoms of PD.

Keywords: DBS; GPi; STN; basal ganglia; depression; hypomania.

PubMed Disclaimer

References

    1. Karlsen KH, Larsen JP, Tandberg E, Maeland JG. Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. (1999) 66:431–5. 10.1136/jnnp.66.4.431 - DOI - PMC - PubMed
    1. Reijnders JSAM, Ehrt U, Weber WEJ, Aarsland D, Leentjens AFG. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord. (2008) 23:183–9; quiz 313. 10.1002/mds.21803 - DOI - PubMed
    1. Hely MA, Morris JGL, Reid WGJ, Trafficante R. Sydney multicenter study of parkinson's disease: non-l-dopa-responsive problems dominate at 15 years. Mov Disord. (2005) 20:190–9. 10.1002/mds.20324 - DOI - PubMed
    1. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, et al. . The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease. Mov Disord. (2009) 24:1325–32. 10.1002/mds.22586 - DOI - PMC - PubMed
    1. Ravina B, Camicioli R, Como PG, Marsh L, Jankovic J, Weintraub D, et al. . The impact of depressive symptoms in early Parkinson disease. Neurology. (2007) 69:342–7. 10.1212/01.wnl.0000268695.63392.10 - DOI - PMC - PubMed